2021

30/08/2021

Annual Report to shareholders

30/08/2021

Preliminary Final Report

30/08/2021

Corporate Governance Statement and Appendix 4G

12/08/2021

Proteomics International contracts Biotem to manufacture PromarkerD test kits

11/08/2021

Conference presentation – Australasian Diabetes Congress 2021

04/08/2021

Proteomics to collaborate to validate test for endometriosis

02/08/2021

Application for quotation of securities

02/08/2021

Exercise of Options and Secondary Trading Notice

30/07/2021

Appendix 4C – June 2021 Quarterly Update

28/07/2021

Manufacturing update and clarification of Abcam engagement

22/07/2021

Proteomics International engages Abcam to manufacture PromarkerD reagents

20/07/2021

Investor Presentation

16/07/2021

Diabetes treatment lowers PromarkerD risk score: Results to be presented at Australasian Diabetes Conference

02/07/2021

Update on study presented at ADA Conference

28/06/2021

World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years

10/06/2021

CCO and CFO appointed to bolster executive team

18/05/2021

Proteomics secures major analytical services contract

13/05/2021

Study demonstrates major economic health benefit of PromarkerD – PromarkerD reimbursement update

30/04/2021

Proposed issue of Securities

30/04/2021

Issue of Options and Secondary Trading Notice

29/04/2021

Appendix 4C – March 2021 Quarterly Update

29/04/2021

Proteomics files US FDA 513(g) regulatory submission

23/04/2021

Proteomics International achieves ISO 13485 certification

15/03/2021

Exercise of Options

09/03/2021

Investor Presentation

26/02/2021

Exercise of Options

25/02/2021

Appendix 4D and Interim Financial Report

16/02/2021

Response to Price Query

08/02/2021

Proteomics International seeks FDA approval for PromarkerD

28/01/2021

Update – Proposed issue of Securities – PIQ

28/01/2021

Issue of Options and Secondary Trading Notice

28/01/2021

Results of Meeting

28/01/2021

Appendix 4C – December 2020 Quarterly Update

Subscribe
  • This field is for validation purposes and should be left unchanged.